Aliu Zanzeh Bankah, Thomas Amatey Tagoe, Emmanuel Darko, Righteous Agoha, Elmer Nayra Ametefe, Kennedy Kwami Edem Kukuia, Samuel Adjei
{"title":"乳杆菌或双歧杆菌联合用药可增强抗抑郁和抗焦虑活性","authors":"Aliu Zanzeh Bankah, Thomas Amatey Tagoe, Emmanuel Darko, Righteous Agoha, Elmer Nayra Ametefe, Kennedy Kwami Edem Kukuia, Samuel Adjei","doi":"10.1002/brb3.70564","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Gut microbiota is strongly linked to the activity of the bidirectional gut-brain axis, which influences neuropsychological processes at multiple levels. Changes in the gut microbiota have been implicated in mood disorders, and probiotics have been explored for their ability to mitigate the effects of stress on mental health. Here, we investigated the therapeutic benefits of different concentrations and combinations of <i>Lactobacillus and Bifidobacterium</i> in a mouse model of stress induced depression and anxiety.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Sixty-three male ICR mice (6–8 weeks old; 20–25g) divided into nine groups were used for this study. The test groups underwent chronic unpredictable mild stress protocols for two weeks before receiving low (10<sup>4</sup> CFU/ml) or high (10<sup>8</sup> CFU/ml) doses of either monotherapy (<i>Lactobacillus</i> or <i>Bifidobacterium</i>) or a combination therapy (<i>Lactobacillus</i> and <i>Bifidobacterium</i>) for four weeks. The antidepressant, fluoxetine, served as the positive control. Measurements of weight and sucrose preference were performed at four time points in addition to a battery of behavioral tests (open field tests, forced swim test, tail suspension test, and hot plate test) at the endpoint to assess depression and anxiety-like behavior.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Low doses of the probiotic formulation (mono- or combined therapy) reversed weight loss but not anhedonia. In contrast, high doses of probiotic formulations (mono- or combined therapy), along with fluoxetine, were effective in reversing the weight loss and anhedonia caused by chronic unpredictable mild stress. Probiotics ameliorated stress-induced immobility as measured by both the forced swim and tail suspension tests, while also reducing anxiety-like behavior (increased peripheral activity) in the open field test. High doses of mono- or combined therapy increased curling behavior in the tail suspension test, whereas fluoxetine failed to do so.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study indicates the species- and dose-dependent beneficial effects of probiotics on behavioral outcomes associated with depression while also reversing weight loss. Evidence suggests that probiotics and fluoxetine may exert antidepressant activity via different mechanisms.</p>\n </section>\n </div>","PeriodicalId":9081,"journal":{"name":"Brain and Behavior","volume":"15 5","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brb3.70564","citationCount":"0","resultStr":"{\"title\":\"Combined Administration of Lactobacillus or Bifidobacterium Offers Enhanced Antidepressant and Anxiolytic Activity in a Dose Dependent Manner\",\"authors\":\"Aliu Zanzeh Bankah, Thomas Amatey Tagoe, Emmanuel Darko, Righteous Agoha, Elmer Nayra Ametefe, Kennedy Kwami Edem Kukuia, Samuel Adjei\",\"doi\":\"10.1002/brb3.70564\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Purpose</h3>\\n \\n <p>Gut microbiota is strongly linked to the activity of the bidirectional gut-brain axis, which influences neuropsychological processes at multiple levels. Changes in the gut microbiota have been implicated in mood disorders, and probiotics have been explored for their ability to mitigate the effects of stress on mental health. Here, we investigated the therapeutic benefits of different concentrations and combinations of <i>Lactobacillus and Bifidobacterium</i> in a mouse model of stress induced depression and anxiety.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Sixty-three male ICR mice (6–8 weeks old; 20–25g) divided into nine groups were used for this study. The test groups underwent chronic unpredictable mild stress protocols for two weeks before receiving low (10<sup>4</sup> CFU/ml) or high (10<sup>8</sup> CFU/ml) doses of either monotherapy (<i>Lactobacillus</i> or <i>Bifidobacterium</i>) or a combination therapy (<i>Lactobacillus</i> and <i>Bifidobacterium</i>) for four weeks. The antidepressant, fluoxetine, served as the positive control. Measurements of weight and sucrose preference were performed at four time points in addition to a battery of behavioral tests (open field tests, forced swim test, tail suspension test, and hot plate test) at the endpoint to assess depression and anxiety-like behavior.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Low doses of the probiotic formulation (mono- or combined therapy) reversed weight loss but not anhedonia. In contrast, high doses of probiotic formulations (mono- or combined therapy), along with fluoxetine, were effective in reversing the weight loss and anhedonia caused by chronic unpredictable mild stress. Probiotics ameliorated stress-induced immobility as measured by both the forced swim and tail suspension tests, while also reducing anxiety-like behavior (increased peripheral activity) in the open field test. High doses of mono- or combined therapy increased curling behavior in the tail suspension test, whereas fluoxetine failed to do so.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This study indicates the species- and dose-dependent beneficial effects of probiotics on behavioral outcomes associated with depression while also reversing weight loss. Evidence suggests that probiotics and fluoxetine may exert antidepressant activity via different mechanisms.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9081,\"journal\":{\"name\":\"Brain and Behavior\",\"volume\":\"15 5\",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-05-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/brb3.70564\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain and Behavior\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/brb3.70564\",\"RegionNum\":3,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BEHAVIORAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Behavior","FirstCategoryId":"102","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/brb3.70564","RegionNum":3,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BEHAVIORAL SCIENCES","Score":null,"Total":0}
Combined Administration of Lactobacillus or Bifidobacterium Offers Enhanced Antidepressant and Anxiolytic Activity in a Dose Dependent Manner
Purpose
Gut microbiota is strongly linked to the activity of the bidirectional gut-brain axis, which influences neuropsychological processes at multiple levels. Changes in the gut microbiota have been implicated in mood disorders, and probiotics have been explored for their ability to mitigate the effects of stress on mental health. Here, we investigated the therapeutic benefits of different concentrations and combinations of Lactobacillus and Bifidobacterium in a mouse model of stress induced depression and anxiety.
Methods
Sixty-three male ICR mice (6–8 weeks old; 20–25g) divided into nine groups were used for this study. The test groups underwent chronic unpredictable mild stress protocols for two weeks before receiving low (104 CFU/ml) or high (108 CFU/ml) doses of either monotherapy (Lactobacillus or Bifidobacterium) or a combination therapy (Lactobacillus and Bifidobacterium) for four weeks. The antidepressant, fluoxetine, served as the positive control. Measurements of weight and sucrose preference were performed at four time points in addition to a battery of behavioral tests (open field tests, forced swim test, tail suspension test, and hot plate test) at the endpoint to assess depression and anxiety-like behavior.
Results
Low doses of the probiotic formulation (mono- or combined therapy) reversed weight loss but not anhedonia. In contrast, high doses of probiotic formulations (mono- or combined therapy), along with fluoxetine, were effective in reversing the weight loss and anhedonia caused by chronic unpredictable mild stress. Probiotics ameliorated stress-induced immobility as measured by both the forced swim and tail suspension tests, while also reducing anxiety-like behavior (increased peripheral activity) in the open field test. High doses of mono- or combined therapy increased curling behavior in the tail suspension test, whereas fluoxetine failed to do so.
Conclusion
This study indicates the species- and dose-dependent beneficial effects of probiotics on behavioral outcomes associated with depression while also reversing weight loss. Evidence suggests that probiotics and fluoxetine may exert antidepressant activity via different mechanisms.
期刊介绍:
Brain and Behavior is supported by other journals published by Wiley, including a number of society-owned journals. The journals listed below support Brain and Behavior and participate in the Manuscript Transfer Program by referring articles of suitable quality and offering authors the option to have their paper, with any peer review reports, automatically transferred to Brain and Behavior.
* [Acta Psychiatrica Scandinavica](https://publons.com/journal/1366/acta-psychiatrica-scandinavica)
* [Addiction Biology](https://publons.com/journal/1523/addiction-biology)
* [Aggressive Behavior](https://publons.com/journal/3611/aggressive-behavior)
* [Brain Pathology](https://publons.com/journal/1787/brain-pathology)
* [Child: Care, Health and Development](https://publons.com/journal/6111/child-care-health-and-development)
* [Criminal Behaviour and Mental Health](https://publons.com/journal/3839/criminal-behaviour-and-mental-health)
* [Depression and Anxiety](https://publons.com/journal/1528/depression-and-anxiety)
* Developmental Neurobiology
* [Developmental Science](https://publons.com/journal/1069/developmental-science)
* [European Journal of Neuroscience](https://publons.com/journal/1441/european-journal-of-neuroscience)
* [Genes, Brain and Behavior](https://publons.com/journal/1635/genes-brain-and-behavior)
* [GLIA](https://publons.com/journal/1287/glia)
* [Hippocampus](https://publons.com/journal/1056/hippocampus)
* [Human Brain Mapping](https://publons.com/journal/500/human-brain-mapping)
* [Journal for the Theory of Social Behaviour](https://publons.com/journal/7330/journal-for-the-theory-of-social-behaviour)
* [Journal of Comparative Neurology](https://publons.com/journal/1306/journal-of-comparative-neurology)
* [Journal of Neuroimaging](https://publons.com/journal/6379/journal-of-neuroimaging)
* [Journal of Neuroscience Research](https://publons.com/journal/2778/journal-of-neuroscience-research)
* [Journal of Organizational Behavior](https://publons.com/journal/1123/journal-of-organizational-behavior)
* [Journal of the Peripheral Nervous System](https://publons.com/journal/3929/journal-of-the-peripheral-nervous-system)
* [Muscle & Nerve](https://publons.com/journal/4448/muscle-and-nerve)
* [Neural Pathology and Applied Neurobiology](https://publons.com/journal/2401/neuropathology-and-applied-neurobiology)